Skip to main content

Table 3 Exclusion criteria for the donor

From: Impact of fecal microbiota transplantation on chronic recurrent pouchitis in ulcerative colitis with ileo-anal anastomosis: study protocol for a prospective, multicenter, double-blind, randomized, controlled trial

1 Exclusion criteria related to general safety
Personal status  
General ➢ Presence of chronic disease
➢ Pregnant or lactating women
➢ Adults under guardianship, safeguard justice, or trusteeship
➢ For donors over the age of 50 years, absence of screening test for colorectal cancer within 2 years and positive test result
Digestive ➢ Celiac disease
➢ Irritable bowel syndrome
➢ Chronic constipation
➢ Diarrhea defined as > 3 very soft or liquid stools per day
➢ Hemorrhoids or rectal bleeding
➢ Personal history of:
• gastrointestinal neoplasia or polyps
• autoimmune or inflammatory disease
• IBD
Diet and drug use ➢ Particular diet (exclusion diet, vegetarian diet) or other specific considerations: ingestion of a potential allergen (e.g. peanut) to which the recipient has a known allergy
➢  → Alcohol or drug abuse
➢ Spouse of a patient with IBD
Family status ➢ First-degree family history of:
• IBD
• gastrointestinal neoplasia or polyps before the age of 60 years
• autoimmune or inflammatory disease
➢ Diarrhea defined as > 3 very soft or liquid stools per day for the family members within 3 months.
2 Exclusion criteria related to prior or concomitant treatment
  ➢ No medication whatsoever in the 48 h before the donation (except contraceptive treatment)
➢ No regular curative medication except oral contraception
➢ Immunosuppressants (e.g. calcineurin inhibitors, corticosteroids, biological agents, etc.) antineoplastic chemotherapy
➢ Antibiotic or antifungal in the previous 3 months before the donation
➢ Non-steroidal anti-inflammatory intake in the previous month for the donation
3 Exclusion criteria related to infection risk
General ➢ Abnormal macroscopic appearance of stool
➢ Known infection by HIV, HTLV virus, hepatitis B or C virus
➢ Positive result in one of the contagious disease testing (see Appendix ANSM)
➢ Existence of anal lesions suggestive of viral infection (papillomas, vesicles, or other lesions)
➢ Multiresistant bacteria carrier (see Appendix ANSM)
➢ Risk of Creutzfeldt–Jakob disease
➢ Personal history of typhoid fever
2 years ➢ Residence in the intertropical zone > 2 years
12 months ➢ Hospitalization abroad > 24 h in the last 12 months (including members of the family)
6 months ➢ Contact with human blood (blood transfusion, piercing, tattoo, etc.) within the previous 6 months
➢ Sexual behavior risk (defined as unprotected sexual contact with a new partner) in the previous 6 months
3 months ➢ Gastroenteritis in the last 3 months
Digestive disorders such as acute or chronic diarrhea in the 3 months preceding the donation
➢ Behavior deemed at risk of infection: travel in the previous 3 months
14 days ➢ Infectious episode 14 days before screening
Blood tests
Biology ➢ Abnormal local lab value concerning the following tests: fasting glucose, blood count, platelets, ferritin, CRP, ionogram, urea, creatinine, AST/ALT, gamma glutamyl transferase, alkaline phosphatase, bilirubin, prothrombin time, activated partial thromboplastin time, lipids (cholesterol, triglycerides)
Virology, bacteriology, and parasitology See Table 2
Stool test
Virology, bacteriology, and parasitology See Table 2
  1. CRP C-reactive protein, HIV human immunodeficiency virus; IBD Irritable Bowel Syndrome